2023
DOI: 10.3390/molecules28196995
|View full text |Cite
|
Sign up to set email alerts
|

Development and Validation of a UHPLC–MS/MS Method for the Quantification of a Novel PYGB Inhibitor in Plasma: Application to Pharmacokinetic Studies

Sumei Xu,
Shuai Li,
Zhiwei Yan
et al.

Abstract: In previous studies, we reported compound 1 (5-chloro-N-(4-oxo-2,2-dipropyl-3,4-dihydro-2H-benzo[e][1,3]oxazin-6-yl)-1H-indole-2-carboxamide) as a novel PYGB inhibitor, and found that it had better anti-ischemic brain injury activity. In this study, we established and validated a novel UHPLC–MS/MS method for the quantitative determination of compound 1 in plasma, then applied the method to study the pharmacokinetic parameters and brain tissue distribution of compound 1 in SD (Sprague—Dawley) rats after intrave… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 31 publications
0
1
0
Order By: Relevance
“…In accordance with the guidelines of the Food and Drug Administration for bioanalytical method validation [ 25 ], the UHPLC-MS/MS method was validated in terms of specificity, linearity, precision, accuracy, extraction recovery, matrix effect, and stability [ 26 , 27 ].…”
Section: Methodsmentioning
confidence: 99%
“…In accordance with the guidelines of the Food and Drug Administration for bioanalytical method validation [ 25 ], the UHPLC-MS/MS method was validated in terms of specificity, linearity, precision, accuracy, extraction recovery, matrix effect, and stability [ 26 , 27 ].…”
Section: Methodsmentioning
confidence: 99%